Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
Holding GB:AZN?
Track your performance easily
AZN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range9,461.00p - 13,388.00p
Previous Close9,985p
Volume455.58K
Average Volume (3M)2.23M
Market Cap
£155.06B
Enterprise Value172.53B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)30.3
Beta0.93
Next Earnings
Nov 12, 2024EPS Estimate
£1.59Last Dividend Ex-Date
Aug 08, 2024Dividend Yield2.36%
Share Statistics
EPS (TTM)3.29
Shares Outstanding1,550,294,658
10 Day Avg. Volume4,000,770
30 Day Avg. Volume2,226,656
Standard Deviation0.06
R-Squared0.10
Alpha0.00878
Financial Highlights & Ratios
Price to Book (P/B)391.72
Price to Sales (P/S)4.19
Price to Cash Flow (P/CF)18.50
P/FCF Ratio25.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.89
Enterprise Value/Gross Profit4.60
Enterprise Value/Ebitda18.99
Forecast
1Y Price Target
13,602.10pPrice Target Upside35.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
AstraZeneca News
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline And Research DevelopmentsAstraZeneca maintains a Buy rating due to a busy pipeline with multiple significant Phase III readouts expected.
Oncology And Drug PotentialAstraZeneca's Dato drug is seen as a significant opportunity, with potential peak sales of $2 billion and promising data in breast cancer.
Valuation And Market PerceptionShares are now down year to date, and valuation looks attractive.
Bears Say
Clinical Trial ResultsFinal OS data for datopotamab from TL01 2L lung data at World Lung underwhelming.
Drug Safety ConcernsThere are concerns about the toxicity of Volrustomig, with a high percentage of Grade 3/4 treatment-related adverse events and discontinuations.
Regulatory And Legal IssuesThe stock has seen a decline of over 10% due to ongoing investigations in China.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
14.70% Mutual Funds
0.02% Other Institutional Investors
76.65% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9461.00p and its highest was 13388.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Nov 12, 2024 which is yesterday.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Jul 25, 2024. The company reported 1.54p earnings per share for the quarter, beating the consensus estimate of 1.528p by 0.012p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 77.6p which represents an annual dividend yield of 2.36%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is £1.59.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,303,800 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.54p in its last earnings report, beating expectations of 1.528p. Following the earnings report the stock price went down -1.261%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,602.10p (35.90% Upside)
13,602.10p (35.90% Upside)
Insider Transactions
Bought Shares
Worth £235.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.12%
12-Months-Change
Fundamentals
Return on Equity
16.83%
Trailing 12-Months
Asset Growth
8.70%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
13,602.10p
▲(35.90% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
28/29 ratings generated profit
1 Year Average Return
+16.98%
reiterated a sell rating 7 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 96.55% of your transactions generating a profit, with an average return of +16.98% per trade.
---